Furuyoshi S, Nakatani M, Taman J, Kutsuki H, Takata S, Tani N
Ther Apher. 1998 Feb;2(1):13-7. doi: 10.1111/j.1744-9987.1998.tb00067.x.
The Lixelle column is an adsorbent column used to eliminate beta2-microglobulin (beta2M) selectively from circulating blood of dialysis related amyloidosis (DRA) patients, which is used in combination with a dialyzer in series. The column has such a high capacity for adsorbing beta2M that the most intensive removal of beta2M has been possible. In clinical trials of the column, the obvious improvement of subjective symptoms such as decreases in the frequency of nocturnal awakening, the joint pain severity index, and the joint mobility index were observed. Hypotension has been the most frequent adverse event observed during treatment since the column was put on the market. It is very important to clarify the causes of both the efficacy and the side effects. A controlled prospective study is now in progress to clarify the efficacy more scientifically. The results will be published soon elsewhere.
利克塞尔柱是一种吸附柱，用于从透析相关性淀粉样变性（DRA）患者的循环血液中选择性清除β2-微球蛋白（β2M），它与透析器串联使用。该柱对β2M具有很高的吸附能力，从而实现了对β2M的最大程度清除。在该柱的临床试验中，观察到诸如夜间觉醒频率降低、关节疼痛严重程度指数和关节活动指数等主观症状有明显改善。自该柱上市以来，低血压一直是治疗期间观察到的最常见不良事件。阐明疗效和副作用的原因非常重要。目前正在进行一项对照前瞻性研究，以便更科学地阐明疗效。结果将很快在其他地方发表。
